ArticleJournal of clinical microbiology2007
Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Article in Journal of clinical microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 1 synthesis or guideline pooled it, 283 citations in OpenAlex.
- Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2009Guideline
- [Yeasts in the lung-colonization or catastrophe? : An infectious disease complication in a patient with acute myeloid leukemia].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026Article
- Cryptococcal antigen cross-reactivity is associated with fatal trichosporonosis in patients with hematologic diseases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Article
- Invasive fungal infections caused by rare yeast-like fungi in adult patients: results of a prospective study.Current medical mycology · 2024Article
- Antifungal susceptibility pattern ofFrontiers in cellular and infection microbiology · 2024Article
- The Spectrum of Pathogenic Yeast Infection in a Tertiary Care Hospital in Assam, India.Cureus · 2022Article
- Clinical, epidemiological, and mycological features of patients with candidemia: Experience in two tertiary referral centers in Iran.Current medical mycology · 2022Article
- Drug Resistance and Biofilm Formation inIranian journal of public health · 2022Article
- Characterisation ofJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- Species Distribution and Antifungal Susceptibility Pattern of Candida Recovered from Intensive Care Unit Patients, Vietnam National Hospital of Burn (2017-2019).Mycopathologia · 2021Article
- Review
- A Novel, Inexpensive In-House Immunochromatographic Strip Test for Cryptococcosis Based on the Cryptococcal Glucuronoxylomannan Specific Monoclonal Antibody 18B7.Diagnostics (Basel, Switzerland) · 2021Article
- Low sensitivity of conventional fungal agars in fungemia by Rhodotorula mucilaginosa: description of two cases.Annals of clinical microbiology and antimicrobials · 2021Article
- Amphotericin B and Other Polyenes-Discovery, Clinical Use, Mode of Action and Drug Resistance.Journal of fungi (Basel, Switzerland) · 2020Review
- Article
- Two cases of fungal cyst infection in ADPKD: is this really a rare complication?BMC infectious diseases · 2019Article
- New transition metal complexes with a pendent indole ring: insights into the antifungal activity and mode of action.RSC advances · 2019Article
- Candida parapsilosis: from Genes to the Bedside.Clinical microbiology reviews · 2019Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2005. Data were collected for 147,776 yeast isolates tested with voriconazole from 2001 through 2005. All investigators tested clinical yeast isolates by the CLSI M44-A disk diffusion method. Test plates were automatically read and results recorded with a BIOMIC image analysis system. Species, drug, zone diameter, susceptibility category, and quality control results were collected quarterly. Duplicate (same patient, same species, and same susceptible-resistant biotype profile during any 7-day period) and uncontrolled test results were not analyzed. Overall, 90.1% of all Candida isolates tested were susceptible (S) to fluconazole; however, 10 of the 22 species identified exhibited decreased susceptibility (<75% S) on the order of that seen with the resistant (R) species C. glabrata and C. krusei. Among 137,487 isolates of Candida spp. tested against voriconazole, 94.8% were S and 3.1% were R. Less than 30% of fluconazole-resistant isolates of C. albicans, C. glabrata, C. tropicalis, and C. rugosa remained S to voriconazole. The non-Candida yeasts (8,821 isolates) were generally less susceptible to fluconazole than Candida spp. but, aside from Rhodotorula spp., remained susceptible to voriconazole. This survey demonstrates the broad spectrum of these azoles against the most common opportunistic yeast pathogens but identifies several less common yeast species with decreased susceptibility to antifungal agents. These organisms may pose a future threat to optimal antifungal therapy and emphasize the importance of prompt and accurate species identification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.